180 Degree Capital Corp. Notes Preliminary Net Asset Value per Share of $4.42 as of March 31, 2025, and Portfolio Company Updates From Q1 2025

Stock Information for Lineage Cell Therapeutics, Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Lineage Cell Therapeutics, Inc.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LNSR, TURN, DNB, GB on Behalf of Shareholders
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: LENSAR, Inc. (Nasdaq - LNSR), 180 Degree Capital Corp. (Nasdaq - TURN), Dun & Bradstreet Holdings, Inc. (NYSE - DNB), Global Blue Group Holding AG (Nasdaq - GB)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LNSR, TURN, DNB, GB on Behalf of Shareholders
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: LENSAR, Inc. (Nasdaq - LNSR), 180 Degree Capital Corp. (Nasdaq - TURN), Dun & Bradstreet Holdings, Inc. (NYSE - DNB), Global Blue Group Holding AG (NYSE - GB)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MHLD, TURN, FNA, PTMN on Behalf of Shareholders
STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating The Merger - SLRN, TURN, BHLB, MHLD
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TURN, RDFN, AMPY, HEES on Behalf of Shareholders
$HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The Merger - SLRN, TURN, BHLB, MHLD

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.